

/mL and 60.3%, respectively^[1].

AR453588 (1 mg/kg; i.v.) treatment shows that the CL, AUC_{inf}, V_{ss}, and t_{1/2} are 21.6 mL/min/kg, 0.77 h µg/mL, 0.746 L/kg and 1.28 hours, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male diabetic ob/ob mice ^[1]
Dosage:	3, 10, 30 mg/kg
Administration:	Orally once-daily for 14 days
Result:	Lowered the fasted blood glucose from the control animals on day 14 as well as the AUC of the OGTT (oral glucose tolerance tests).

Animal Model:	Male CD-1 mice ^[1]
Dosage:	10 mg/kg
Administration:	p.o. (Pharmacokinetic Analysis)
Result:	The T _{max} , AUC _{inf} , V _{ss} , C _{max} and F were 1.0 mL/min/kg, 4.65 h µg/mL, 1.67 µg/mL and 60.3%, respectively.

REFERENCES

[1]. Hinklin RJ, et al. Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator. *Bioorg Med Chem.* 2020 Jan 1;28(1):115232.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA